Synolo Therapeutics develops logic‑gated immunotherapies that are conditionally active only in the presence of specific disease biomarkers, aiming to treat cancer and autoimmune disorders with greater efficacy and safety. Leveraging a proprietary discovery platform, the company is rapidly building a pipeline of differentiated therapeutics that activate immune responses selectively at tumor or inflamed sites, reducing off‑target effects compared with existing standard‑of‑care treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer and autoimmune therapies often activate the immune system systemically, leading to off‑target toxicity and limited therapeutic windows. Patients may experience severe side effects, and efficacy can be constrained by the inability to precisely target diseased tissues.
Solution
Synolo Therapeutics creates conditionally‑active immunotherapies that incorporate “logic‑gated” activation mechanisms. These biologics remain inert until they encounter a predefined combination of disease‑specific markers, such as tumor antigens and inflammatory cues, at the target site. By requiring multiple molecular inputs before triggering immune activation, the approach aims to deliver potent therapeutic effects while minimizing collateral damage to healthy tissue. The company leverages a proprietary discovery platform to identify suitable marker sets and engineer the gating circuitry into antibody‑based or cellular therapeutics. This strategy is applied to both oncology and autoimmune indications, seeking to improve efficacy and safety compared with existing standard‑of‑care treatments.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing oncology or autoimmune pipelines that require targeted immune activation with reduced systemic toxicity.
Features
- Multi‑input logic gates (e.g., AND/OR) that couple antigen recognition with microenvironmental signals to control therapeutic activation
- Proprietary platform for rapid discovery and validation of disease‑specific marker combinations
- Engineered antibody or cell‑based constructs capable of conditional cytokine release or cytotoxic activity
- Built‑in safety switches that abort activation if off‑target markers are detected
- Modular design allowing adaptation of the gating system to a variety of cancer and autoimmune targets